|Share Name||Share Symbol||Market||Type||Share ISIN||Share Description|
|GlaxoSmithKline||LSE:GSK||London||Ordinary Share||GB0009252882||ORD 25P|
|Price Change||% Change||Share Price||Bid Price||Offer Price||High Price||Low Price||Open Price||Shares Traded||Last Trade|
|Industry Sector||Turnover (m)||Profit (m)||EPS - Basic||PE Ratio||Market Cap (m)|
|Pharmaceuticals & Biotechnology||27,889.0||1,939.0||18.8||89.2||82,322.75|
GlaxoSmithKline PLC GSK 2016 Form 20F
UK Regulatory (RNS & others)
RNS Number : 8751Z
17 March 2017
Annual Report 2016 on Form 20-F
In accordance with Section 203.01 of the New York Stock Exchange Listed Company Manual, GlaxoSmithKline plc ("GSK") announces that on 17 March 2017 it filed with the Securities and Exchange Commission an Annual Report on Form 20-F that included audited financial statements for the year ended 31 December 2016. GSK's 2016 Annual Report on Form 20-F is available online at GSK's website at www.gsk.com/corporatereporting and also online at www.sec.gov.
Ordinary Shareholders may also elect to receive notification by email of the publication of financial reports by registering on www.shareview.co.uk.
A hard copy version of the GSK 2016 Annual Report, together with the Annual Summary and Notice of Annual General Meeting will be available on or about 30 March 2017.
Shareholders have the ability to receive, upon request, a hard copy version of GSK's complete audited financial statements for the year ended 31 December 2016, free of charge, by either:
(i) writing to Equiniti Limited, our registrars in the UK, at the following address: Equiniti Limited, Aspect House, Spencer Road, Lancing, West Sussex BN99 6DA, or by telephone on 0371 384 2991 (inside the UK) or +44 (0)121 415 7067 (outside the UK);
(ii) writing to The Bank of New York Mellon, our ADR depositary in the US, at the following address: BNY Mellon, Shareholder Services, Receipts, PO Box 30170, College Station, Texas, TX 77842-3170, or by telephone on +1 877 353 1154 (US toll free) or +1 201 680 6825 (outside the US); or
(iii) contacting the GSK Response Center in the USA at +1 888 825 5249 (US toll free).
17 March 2017
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2016.
This information is provided by RNS
The company news service from the London Stock Exchange
(END) Dow Jones Newswires
March 20, 2017 03:00 ET (07:00 GMT)
1 Year GlaxoSmithKline Chart
1 Month GlaxoSmithKline Chart